Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT06093932

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06093932
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06093932. Randomized; double masking; primary purpose treatment. Start 2024-04-07 (actual); primary completion 2024-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial
Acronym
ESCIHP
Condition
Hypertension,Essential
Intervention (Drug)
Songling Xuemaikang Capsules
Intervention (Behavioral)
Lifestyle intervention
Intervention (Drug)
Placebo
Lead sponsor
Xiyuan Hospital of China Academy of Chinese Medical Sciences (class: other)
Collaborator
Suzhou Hosptial of Traditional Chinese Medicine (class: not stated)
Collaborator
Shandong University of Traditional Chinese Medicine (class: other)

Record details

Record id
cardio:ct-nct06093932
Content hash
4364f685ada2a5cac89c495ecdcad0265ea30a2cf0c4b6ca9fdee9179bfda624